GSK126

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Data not yet available

No registered interventional trial or approval record places this drug in the pipeline yet.

Curated evidence

Clinical evidence (8)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–8 of 8 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EZH2 A692V1
GSK126	B Acute Lymphoblastic Leukemia

Clinical trials

Trials with this intervention (0)

Data not yet available

No registered study lists this drug as an intervention yet.

EZH2 Y6462
GSK126	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID1494 Preclinical study in melanoma cell lines. EZH2 expression was higher in EZH2 mutant (N=3) and wild-type melanoma cell lines (N=12) than untransformed cells (human epithelial melanocytes and human derm… (full text at CIViC) PMID 26304929 · Tiffen et al., 2015 · Open in CIViC	civic
Dabrafenib + GSK126 + JQEZ5 + UNC1999Combination	Melanoma	Predictive	D	Supports Sensitivity Response	5	rejected	EID5677 Additional diseases: GC-DLBCL, Follicular lymphoma (FL). Y641 mutations are present in about 20% of GC-DLBCL, 10% FL, and 5% Melanoma (from TCGA/cBioportal). Also note that Y641 and Y646 mutations ar… (full text at CIViC) PMID 27135738 · Souroullas et al., 2016 · Open in CIViC	civic

EZH2 Y646F1
GSK126	Diffuse Large B-Cell LymphomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	submitted	EID11106 EZH2 inhibitor, GSK126, showed high potency against DLBCL cell lines, WSU-DLCL2 and SU-DHL-10, harboring the Y646F variant. Cell proliferation inhibition was measured after six days at growth IC50= 13… (full text at CIViC) PMID 23051747 · McCabe et al., 2012 · Open in CIViC	civic

EZH2 Y646N1
GSK126	Diffuse Large B-Cell LymphomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	submitted	EID11105 EZH2 inhibitor, GSK126, showed high potency against DLBCL cell line, KARPAS-422, which harbors the variant Y646N, and resulted in cellular proliferation inhibition after six days (growth IC50 = 232 n… (full text at CIViC) PMID 23051747 · McCabe et al., 2012 · Open in CIViC	civic

EZH2 Overexpression1
GSK126 + TazemetostatSequential	Neuroblastoma	Predictive	D	Supports Sensitivity Response	2	submitted	EID9115 Within this preclinical study, 87 patients with neuroblastoma and 14 neuroblastoma cell lines were evaluated for overexpression of EZH2 and possible prognostic factors. In patient samples the average … (full text at CIViC) PMID 28214660 · Bate-Eya et al., 2017 · Open in CIViC	civic

MYCN Amplification1
GSK126 + JQEZ5Substitutes	Neuroblastoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID6020 In a genome-scale CRISPR-Cas9 screening of MYCN-amplified neuroblastoma dependency on genes encoding the polycomb repressive complex 2 (PRC2) components EZH2, EED, and SUZ12 was identified. Genetic an… (full text at CIViC) PMID 29202477 · Chen et al., 2018 · Open in CIViC	civic

ARID1A Loss1
GSK126	Ovarian Clear Cell CarcinomaUNRESOLVED	Predictive	D	Supports Sensitivity Response	4	accepted	EID2983 A screen was performed to identify small molecule inhibitors that inhibit growth of ARID1A inactivated cells using shRNA knockdown in ARID1A wild-type ovarian clear cell carcinoma (OCCC) cell line RMG… (full text at CIViC) PMID 25686104 · Bitler et al., 2015 · Open in CIViC	civic